Malattie demielinizzanti acquisite in età evolutiva

Neurologia

Dr.ssa Laura Siri*,

Dr.ssa Fabiana Vercellino**

*Dirigente Medico, U.O.C. Neuropsichiatria Infantile IRCCS, Ist. G. Gaslini, Genova

**SOC Neuropsichiatria Infantile Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria, Italy, EU

laura.siri@libero.it ,

fvercellino@ospedale.al.it

Il Pediatra, n.4-20, pagg. 48-54

Bibliografia

1. Neuteboom RF, Wilbur C, Van Pelt ED, Rodriguez M, Yeh EA. The spectrum of inflammatory acquired demyelinating syndromes in children. Semin Pediatr Neurol. 2017 Aug;24(3):189-200. doi: 10.1016/j.spen.2017.08.007.
2. Efendi H. Clinically isolated syndromes: clinical characteristics, differential diagnosis and management. Noro Psikiyatr Ars. 2015 Dec;52(Suppl 1):S1-S11. doi: 10.5152/npa.2015.12608.
3. Langer-Gould A, Zhang JL, Chung J, Yeung Y, Waubant E, Yao J. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology. 2011 Sep 20;77(12):1143-8. doi: 10.1212/WNL.0b013e31822facdd.
4. Banwell B, Kennedy J, Sadovnick D, Arnold DL, Magalhaes S, Wambera K, Connolly MB, Yager J, Mah JK, Shah N, Sebire G, Meaney B, Dilenge ME, Lortie A, Whiting S, Doja A, Levin S, MacDonald EA, Meek D, Wood E, Lowry N, Buckley D, Yim C, Awuku M, Guimond C, Cooper P, Grand’Maison F, Baird JB, Bhan V, Bar-Or A. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009 Jan 20;72(3):232-9. doi: 10.1212/01.wnl.0000339482.84392.bd.
5.  Absoud M, Lim MJ, Chong WK, De Goede CG, Foster K, Gunny R, Hemingway C, Jardine PE, Kneen R, Likeman M, Nischal KK, Pike MG, Sibtain NA, Whitehouse WP, Cummins C, Wassmer E; UK and Ireland Childhood CNS Inflammatory Demyelination Working Group. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Multiple Sclerosis Journal 2013 Jan;19(1):76-86. doi: 10.1177/1352458512445944.
6. Pröbstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. Journal of Neuroinflammation. 2015 Mar 8;12:46. doi: 10.1186/s12974-015-0256-1.
7. Jancic J, Nikolic B, Ivancevic N, Djuric V, Zaletel I, Stevanovic D, Peric S, van den Anker JN, Samardzic J. Multiple Sclerosis in Pediatrics: Current Concepts and Treatment Options. Neurol Ther. 2016 Dec;5(2):131-143
8. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2.
9. 2017 McDonald diagnostic criteria: A review of the evidence. McNicholas N, Hutchinson M, McGuigan C, Chataway J. Mult Scler Relat Disord. 2018 Aug;24:48-54. doi: 10.1016/j.msard.2018.05.011
10. Clinical Application of 2017 McDonald Diagnostic Criteria for Multiple Sclerosis. Mantero V, Abate L, Balgera R, La Mantia L, Salmaggi A. J Clin Neurol. 2018 Jul;14(3):387-392. doi: 10.3988/jcn.2018.14.3.387
11. Clinical and MRI phenotype of children with MOG antibodies. Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, Healy B, McLaughlin K, Wucherpfennig KW, Chitnis T. Mult Scler. 2016 Feb;22(2):174-84. doi: 10.1177/1352458515587751.
12. McLaughlin KA1, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, Kuhle J, Kappos L, Rostasy K, Pohl D, Gagne D, Ness JM, Tenembaum S, O’Connor KC, Viglietta V, Wong SJ, Tavakoli NP, de Seze J, Idrissova Z, Khoury SJ, Bar-Or A, Hafler DA, Banwell B, Wucherpfennig KW. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol. 2009 Sep 15;183(6):4067-76. doi: 10.4049/jimmunol.0801888.